Back to Journals » Drug Design, Development and Therapy » Nanotechnology in Drug Delivery for Neurodegenerative Diseases
Drug Design, Development and Therapy
- View all (5535)
- Volume 20, 2026 (304)
- Volume 19, 2025 (762)
- Volume 18, 2024 (430)
- Volume 17, 2023 (283)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Journal Articles:
- Modern Computational Approaches for Drug Design and Discovery (3)
- Advances in p53 Drug Discovery (4)
- Nanotechnology in Drug Delivery for Neurodegenerative Diseases (2)
- New Trends in Formulations for Oral Inhalation (1)
- Exploring Fragment-Based Approaches in Drug Discovery (2)
- Advances in design and development of ophthalmic drugs (9)
- Using Innovative Drug Delivery Systems to Improve the Efficacy and Applicability of Poorly Water-soluble Drugs (4)
- Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System (1)
- A cross-sectional survey on heart failure from China: disease burden and management (3)
- Ten Years of Biosimilars in Europe (4)
Nanotechnology in Drug Delivery for Neurodegenerative Diseases
Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD), are marked by progressive neuronal loss, resulting in severe cognitive and motor impairments. According to the World Health Organization, AD alone affects over 50 million people globally, with projections suggesting this number could triple by 2050. Current treatments are limited in efficacy, primarily due to the blood-brain barrier (BBB), which restricts the entry of most therapeutic agents into the brain. Nanotechnology offers a promising solution to overcome the challenges posed by the BBB.
Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery
Rananaware P, Narayan M, Brahmkhatri V
Drug Design, Development and Therapy 2026, 20:562785
Published Date: 23 February 2026
Therapeutic Efficacy of Curcumin Nanoparticles in Parkinson’s Disease: An Integrated Analysis of Network Pharmacology, Experimental Validation, and Gut Microbiota
Mu R, Liu T, Zhang Y, Xiu K, Guo X, Xia W
Drug Design, Development and Therapy 2026, 20:566113
Published Date: 22 January 2026